Last reviewed · How we verify
azithromycin, doxycycline
At a glance
| Generic name | azithromycin, doxycycline |
|---|---|
| Also known as | azithromycin, doxycycline |
| Sponsor | Samsung Medical Center |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial (PHASE2)
- Precision Medicine Approach for Early Dementia & Mild Cognitive Impairment (PHASE3)
- the PHENOSAR Trial: Use of Antibiotics in Treatment of Sarcoidosis (NA)
- Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants
- Scrub Typhus Antibiotic Resistance Trial (PHASE4)
- Doxycycline vs. Macrolide for MRMP (DOMINO) (PHASE4)
- Periodic Presumptive Treatment vs. doxyPEP for STI Control in Kenyan MSM (PHASE4)
- Azithromycin Versus Doxycycline in Hospitalized Adult Patients With Community Acquired Pneumonia Treated With Beta-lactams (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- azithromycin, doxycycline CI brief — competitive landscape report
- azithromycin, doxycycline updates RSS · CI watch RSS
- Samsung Medical Center portfolio CI